| Myristoylation and membrane binding regulate c-Src stability and kinase activity P Patwardhan, MD Resh Molecular and cellular biology 30 (17), 4094-4107, 2010 | 207 | 2010 |
| Processive phosphorylation: mechanism and biological importance P Patwardhan, WT Miller Cellular signalling 19 (11), 2218-2226, 2007 | 132 | 2007 |
| Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs PP Patwardhan, O Surriga, MJ Beckman, E de Stanchina, RP Dematteo, ... Clinical cancer research 20 (12), 3146-3158, 2014 | 123 | 2014 |
| MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma EK Slotkin, PP Patwardhan, SD Vasudeva, E de Stanchina, WD Tap, ... Molecular cancer therapeutics 14 (2), 395-406, 2015 | 112 | 2015 |
| Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models … PP Patwardhan, KS Ivy, E Musi, E de Stanchina, GK Schwartz Oncotarget 7 (4), 4093, 2015 | 102 | 2015 |
| Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth P Patwardhan, Y Shen, GS Goldberg, WT Miller Journal of Biological Chemistry 281 (30), 20689-20697, 2006 | 48 | 2006 |
| Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies TN Sheikh, PP Patwardhan, S Cremers, GK Schwartz Oncotarget 8 (55), 94054, 2017 | 30 | 2017 |
| Preclinical evaluation of nintedanib, a triple angiokinase inhibitor, in soft-tissue sarcoma: potential therapeutic implication for synovial sarcoma PP Patwardhan, E Musi, GK Schwartz Molecular Cancer Therapeutics 17 (11), 2329-2340, 2018 | 15 | 2018 |
| Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve … GA Manji, BA Van Tine, SM Lee, A Raufi, P Patwardhan, LE Blumberg, ... Journal of Clinical Oncology 37 (15_suppl), 11055-11055, 2019 | 9 | 2019 |
| Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors. GA Manji, P Patwardhan, SM Lee, N Matos, E Bentlyewski, BA Van Tine, ... Journal of Clinical Oncology 34 (15_suppl), TPS11070-TPS11070, 2016 | 8 | 2016 |
| Combination treatment with SAHA and 5-Azacytidine (Decitabine) induces apoptosis and suppresses tumor growth in preclinical models of chondrosarcoma T Sheikh, P Patwardhan, GK Schwartz Cancer Research 77 (13_Supplement), 5066-5066, 2017 | 4 | 2017 |
| Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma. M Ingham, SM Lee, P Patwardhan, E Choy, I Chen, S Singh-Kandah, ... Journal of Clinical Oncology 35 (15_suppl), TPS11082-TPS11082, 2017 | 4 | 2017 |
| Synthesis of functional signaling domains by combinatorial polymerization of phosphorylation motifs P Patwardhan, K Shiba, C Gordon, BP Craddock, M Tamiko, WT Miller ACS chemical biology 4 (9), 751-758, 2009 | 4 | 2009 |
| CB839, an orally bioavailable glutaminase inhibitor, shows potent antitumor activity in vitro against models of soft tissue sarcoma and chondrosarcoma TN Sheikh, PP Patwardhan, S Cremers, GK Schwartz Cancer Research 75 (15_Supplement), 4450-4450, 2015 | 3 | 2015 |
| Abstract A30: preclinical study of a combination of mocetinostat (HDAC inhibitor) and 5-AZA-dC (decitabine) in chondrosarcoma TN Sheikh, P Patwardhan, GK Schwartz Clinical Cancer Research 24 (2_Supplement), A30-A30, 2018 | 2 | 2018 |
| Neurofibromatosis type 1 (NF1) status determines sensitivity of soft tissue sarcoma and melanoma cell lines to glutaminase inhibitors TN Sheikh, PP Patwardhan, GK Schwartz Cancer Research 76 (14_Supplement), 19-19, 2016 | 2 | 2016 |
| Preclinical study of a combination of mocetinostat (HDAC inhibitor) and 5-AZA-dC (decitabine) in chondrosarcoma TN Sheikh, P Patwardhan, GK Schwartz, H Irving CLINICAL CANCER RESEARCH 24 (2), 51-52, 2018 | 1 | 2018 |
| Preclinical development of a novel multi-targeted kinase inhibitor, MG516, for the treatment of sarcoma KS Ivy, PP Patwardhan, GK Schwartz Cancer Research 74 (19_Supplement), 1751-1751, 2014 | 1 | 2014 |
| Abstract PO-052: Combinatorial targeting of chromatin and metabolism for synergistic anti-cancer efficacy TN Sheikh, X Chen, X Xu, PP Patwardhan, GK Schwartz, C Lu Cancer Research 80 (23_Supplement), PO-052-PO-052, 2020 | | 2020 |
| Pre-clinical evaluation of CDK4/6 inhibitor resistance and immunologic modification in liposarcoma E Musi, PP Patwardhan, M Ingham, GK Schwartz Cancer Research 80 (16_Supplement), 5289-5289, 2020 | | 2020 |
